Bile duct adenoma

Summary

Bile duct adenoma (MONDO:0006108) is a cancer and 2 clinical trials. A subtype of digestive system adenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bile duct adenoma
Mondo ID	MONDO:0006108
EFO	EFO:1000123
MeSH	D002759
DOID	DOID:5381
NCIT	C2942
SNOMED CT	424091006
UMLS	C0008309
MedGen	918
Anatomy (UBERON)	UBERON:0002394
Is cancer (heuristic)	yes

Also known as: adenoma of bile duct · adenoma of the bile duct · bile duct adenoma · bile duct adenoma (morphologic abnormality) · Cholangioadenoma · Cholangioma · CHOLANGIOMA, benign · Hepatocholangiocellular adenoma · Hepatocholangioma

Disease family

This is a subtype of digestive system adenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › adenoma › digestive system adenoma › bile duct adenoma

Related subtypes (5): colorectal adenoma, gallbladder adenoma, gastric adenoma, Warthin tumor, adenoma of small intestine

Subtypes (3): bile duct cystadenoma, intrahepatic bile duct adenoma, extrahepatic bile duct adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Raltitrexed.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05148143	PHASE2	UNKNOWN	RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
NCT03951324	Not specified	UNKNOWN	Volumetric Laser Endomicroscopy’s (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study